REEV Secures Significant Funding for Innovative Mobility Solutions
REEV has emerged as a groundbreaking force in the medical technology arena, particularly focusing on mobility assistance for individuals grappling with gait disorders. The company recently announced the successful completion of a considerable funding round amounting to $9.2 million. This financial boost is poised to accelerate REEV's endeavors in developing intelligent wearable robotics designed to facilitate movement for patients experiencing mobility challenges.
Vision and Mission of REEV
At the heart of REEV's mission is the desire to improve the quality of life for patients affected by movement disorders. The startup emphasizes creating lightweight, user-friendly technology that not only aids in mobility but also empowers individuals to reclaim their independence and confidence. The latest funding round is set to propel REEV toward its ambitious goal of transforming how mobility assistance is delivered in healthcare.
Key Supporters of the Funding Round
The funding initiative was spearheaded by recognized investors including Newfund Heka, Polytechnique Ventures, and Irdi Capital. This collaboration was further enriched by contributions from diverse sources, including business angels and historical figures like Raphael Varane, a renowned sports personality, and knee surgeon Herve Silbert, who were brought together by Scala Patrimoine, a family office with a keen interest in innovative health solutions.
Innovative Technologies at Work
REEV's technology portfolio showcases two groundbreaking products that are central to its mission:
— REEV SENSE: A sophisticated motion sensor that can be conveniently attached to a patient's footwear or leg, offering precise gait analysis that is crucial for tailoring mobility solutions.
— DREEVEN: This is a state-of-the-art wearable robotic system employing electro-hydraulic technology to deliver personalized knee assistance, ensuring more effective support and rehabilitation for users.
Revolutionizing Exoskeleton Technologies
Existing exoskeleton technologies often face criticism for being bulky, expensive, and not sufficiently personalized. REEV seeks to address these limitations by creating devices that are notably lighter, more affordable, and tailored to individual user needs. The first iteration of the DREEVEN series is anticipated to hit the market in 2026, marking a new era in assistive robotics.
Recent Milestones and Ventures
REEV's journey is punctuated with significant achievements that underscore its dedication to innovation:
— The company has successfully initiated a clinical study at a prestigious research institution, focusing on clinical and translational research with substantial backing from the Massachusetts Technology Collaborative’s eHealth Institute.
— REEV has recently manufactured 100 commercial units of REEV SENSE, gaining both FDA and CE medical certifications, establishing the product's readiness for broader market introduction.
— Additionally, DREEVEN functional units are currently participating in initial testing phases with patients, providing valuable insights for further development.
Future Directions and Goals
The influx of $9.2 million in funding will not only finalize the designs for the DREEVEN system but will also facilitate extensive clinical studies at the Neuromotor Recovery Lab located within Boston University’s Sargent College of Health & Rehabilitation Sciences. Under the expert guidance of Dr. Lou Awad, these trials are aimed at ensuring the safety and efficacy of DREEVEN prior to pursuing FDA trials.
"With the backing of our exceptional partners, we are excited to embark on this pivotal phase of growth and development," shared Amaury Ciurana, Co-Founder and CEO of REEV. The commitment to redefining mobility assistance is evident in his words.
Moreover, Anne-Sophie Saint-Martin, a Partner at Newfund, expressed enthusiasm for the collaboration, emphasizing the importance of supporting REEV in navigating the pathway to FDA clearance. This aligns with their shared mission of enhancing mobility solutions for neurological patients.
About REEV
Founded in 2021, REEV is a forward-thinking medtech startup dedicated to transforming the landscape of mobility assistance. The company specializes in the development of intelligent, lightweight wearable robotics aimed at enhancing the quality of life for patients experiencing challenges in walking. Co-founded by Amaury Ciurana and Dr. Robin Temporelli, REEV has expanded into a passionate team of 30, with bases in both Boston and Toulouse. As a company, they are committed to harnessing technology to restore independence and enhance mobility for those in need.
Frequently Asked Questions
What is the main focus of REEV's technology?
REEV focuses on developing intelligent wearable robotics designed to assist individuals with gait disorders, enhancing their mobility and independence.
Who are the key investors in REEV's recent funding round?
The funding round was led by Newfund Heka, Polytechnique Ventures, and Irdi Capital, with contributions from various business angels and healthcare operators.
What technologies is REEV developing?
REEV is developing two main solutions: the REEV SENSE motion sensor system for gait analysis and the DREEVEN wearable robotics system for personalized knee assistance.
When is the DREEVEN system expected to launch?
The first series of the DREEVEN system is projected to launch in 2026, aiming to provide cutting-edge mobility support.
How is REEV contributing to clinical research?
REEV is conducting clinical studies at institutions like the Neuromotor Recovery Lab at Boston University to ensure the efficacy and safety of its products as it approaches FDA trials.
